Skip to content

Author

Jie Wang

We have 5 of 19 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Sep 2026

Early stage nonsmall cell lung cancer: Toward a risk‐adaptive paradigm in the era of biologic precision

Abstract The clinical landscape of early stage nonsmall cell lung cancer is at transformative crossroads. Driven by the widespread adoption of low‐dose computed tomography screening, the frequent detection of ground‐glass opacities, and a rising incidence among never‐smokers, the diagnostic center of gravity has shifte...

Chao-Qi Zhang, Xuan-Yu Gu, Pan-Hong Wang et al. · 1 citation
Open access Oct 2026

Co-targeting KRAS and BCL-2 induces pyroptosis and antitumor tertiary lymphoid structures

It is established that combined KRAS and BCL-2 inhibition elicits pyroptosis and TLS formation, leading to B-cell-dependent in situ and memory antitumor immunity, providing a mechanistic rationale for targeting mitochondrial-immune crosstalk in KRAS G12D-mutant lung cancer.

Xu Yang, Man Li, Jian Zhang et al. · 0 citations
Aug 2026

EGFR-targeting ADCs: From oncogene addiction to antigen-guided drug delivery.

In this issue of Cancer Cell, Li et al. report a first-in-human phase 1 study of SYS6010, an epidermal growth factor receptor (EGFR)-targeting antibody-drug conjugate, in advanced solid tumors. The study highlights how EGFR-directed therapy moves beyond kinase inhibition toward antigen-guided cytotoxic delivery in non-...

Li-Hui Liu, Kai-Lun Fei, Jie Wang · 0 citations
Open access Aug 2026

Comparative safety profiles of antibody-drug conjugates: a real-world analysis of monotherapy and combination regimens in solid tumors

Abstract The expanding clinical use of Antibody-Drug Conjugates (ADCs) necessitates a clearer understanding of their real-world toxicity profiles across diverse clinical settings. This retrospective pharmacovigilance study analyzed 19,697 adverse event (AE) reports for seven approved ADCs from the FDA Adverse Event Rep...

Linjie Fan, Yu-Ze Yin, W. Zhuang et al. · 0 citations
Open access Aug 2026

Genomic Profiling, Risk Stratification, and Post-Transformation Treatment Outcomes in Patients with Transformed Small-Cell Lung Cancer: A Multicenter Analysis.

Age, RB1/NTRK1 mutation, and secondary T790M mutation were identified as independent risk factors and integrated into a predictive model with high accuracy and establish a clinically applicable model for early prediction and risk stratification of SCLC transformation.

Ruolin Gao, Zhenxiang Li, Jie-Ying Huang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.